From $149/mo Steady, sustained weight loss 20.2% Illustrative trajectory modeled on SURMOUNT-5 (NEJM, 2025), which reported a mean 20.2% body-weight reduction at 72 weeks with tirzepatide at the maximum tolerated dose
* The information provided is the expert opinion of the First Exposure Medical Advisors
GLP-1 agonists can be a powerful tool to manage diabetes and control weight, but like any medication, theyre not without risks, so talking with your doctor is always a good choice.
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial
As neurological and medical complications after stroke are not properly predicted, prevented, or dealt with, they are considered to constitute the main cause of the high morbidity and mortality associated with strokes (78)
My own experience was positive, so it is possible operations have improved
